Author

D. K. Abankwa

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 3 Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:clustering· 1

Frequent Co-Authors

A. Gaigneaux· 2 shared G. b. Manoharan· 2 shared K. Pavic· 2 shared A. Kiriazis· 1 shared A. Yeste-Vazquez· 1 shared B. Parisi· 1 shared C. L. Steffen· 1 shared C. Laurini· 1 shared

Activity by Year

2023-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

A. Gaigneaux

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

RAS isoform specific activities are disrupted by disease associated mutations during cell differentiation

R. Chippalkatti, B. Parisi, F. Kouzi, C. Laurini, N. Ben Fredj, D. K. Abankwa

This study investigates how RAS isoform mutations affect cell differentiation using C2C12 myoblasts, finding distinct roles for K-Ras, N-Ras, and H-Ras and differential effects of pathway drugs.

bioRxiv · Oct 5, 2023Cell Biology

Identification of an H-Ras nanocluster disrupting peptide

G. b. Manoharan, C. L. Steffen, K. Pavic, A. Yeste-Vazquez, M. Knuuttila, N. Arora, Y. Zhou, H. Harma, A. Gaigneaux, T. N. Grossmann, D. K. Abankwa

The paper identifies a peptide that disrupts the interaction between Gal1 and B-Raf-RBD, reducing H-Ras nanoclustering and MAPK signaling in cancer cells.

bioRxiv · Sep 7, 2023 · PreprintBiochemistry

An improved PDE6D inhibitor combines with Sildenafil to synergistically inhibit KRAS mutant cancer cell growth

P. Kaya, E. Schaffner-Reckinger, G. B. Manoharan, V. Vukic, A. Kiriazis, M. Ledda, M. Burgos, K. Pavic, A. Gaigneaux, E. Glaab, D. K. Abankwa

The paper develops a novel PDE6D inhibitor, Deltaflexin3, which synergizes with Sildenafil to inhibit KRAS mutant cancer cell growth, though survival data suggest further exploration of K-Ras and PDE6D interplay.

bioRxiv · Aug 23, 2023Biochemistry